Immuneering Co. (NASDAQ:IMRX) Short Interest Update

Immuneering Co. (NASDAQ:IMRX - Get Free Report) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 1,420,000 shares, a decrease of 12.9% from the February 28th total of 1,630,000 shares. Based on an average daily volume of 1,700,000 shares, the short-interest ratio is currently 0.8 days. Approximately 5.5% of the shares of the stock are short sold.

Hedge Funds Weigh In On Immuneering

Several institutional investors have recently modified their holdings of IMRX. Rockefeller Capital Management L.P. acquired a new stake in shares of Immuneering in the 4th quarter valued at approximately $390,000. First Manhattan CO. LLC. acquired a new stake in Immuneering in the fourth quarter worth $71,000. Bridgeway Capital Management LLC boosted its position in shares of Immuneering by 77.4% during the fourth quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company's stock worth $113,000 after purchasing an additional 22,400 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Immuneering in the 4th quarter valued at $47,000. Finally, XTX Topco Ltd increased its position in shares of Immuneering by 177.2% in the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock valued at $72,000 after buying an additional 20,871 shares in the last quarter. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and issued a $12.00 price target on shares of Immuneering in a report on Friday, March 21st. Morgan Stanley cut Immuneering from an "equal weight" rating to an "underweight" rating in a research note on Friday, December 13th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $13.00 price target on shares of Immuneering in a research note on Monday, March 24th.

Immuneering Stock Down 6.6 %

NASDAQ IMRX traded down $0.10 during trading hours on Friday, hitting $1.41. The company's stock had a trading volume of 154,310 shares, compared to its average volume of 2,367,802. Immuneering has a twelve month low of $1.00 and a twelve month high of $3.83. The firm has a market capitalization of $50.60 million, a P/E ratio of -0.72 and a beta of -0.25. The stock has a fifty day moving average of $1.70 and a 200 day moving average of $1.99.

Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.16). On average, analysts predict that Immuneering will post -1.86 earnings per share for the current year.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.